ER

New zero-click preprocessing automatically identifies invasive carcinoma and excludes DCIS, LCIS, and control tissue before ER, PR, HER2, and Ki67 quantification. Shown here is the HALO Breast IHC AI out put of a stained HER2 slide with AI overlay only in the regions of invasive cancer.

Indica Labs Advances Breast Cancer AI with Zero-Click Tissue Classification Prior to Biomarker Analysis

HALO AP, News, Press Releases / , , , , , , ,

Albuquerque, NM, July 28, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced new intelligent tissue classification capabilities for HALO Breast IHC AI, its AI-powered breast biomarker quantification suite, seamlessly deployed in HALO AP®. This enhanced new version introduces fully automated identification and exclusion of positive control tissue, ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), and areas of benign tissue prior to biomarker analysis. This zero-click preprocessing and tissue classification workflow represents a critical step in ensuring accurate and reproducible AI outputs.

Indica Labs Advances Breast Cancer AI with Zero-Click Tissue Classification Prior to Biomarker Analysis Read More »

Indica Labs' HER2 low and ultralow UI

Low and Ultralow HER2 Expression in Breast Cancer is Now Detectable by Indica Labs’ Breast IHC AI

Breast IHC AI, HALO AP, HALO Clinical AI, News, Press Releases / , , , , , ,

Albuquerque, NM, April 30, 2025 – Indica Labs, the leading provider of AI-powered digital pathology solutions, announces today an update to their Breast IHC AI suite, an image analysis tool used for the quantification of HER2, ER, PR, and Ki67 within AI-identified, tumor regions, of breast cancer tissue specimens. The HER2 algorithm will now include functionality for the detection of low and ultralow HER2 expression in breast cancer.

Low and Ultralow HER2 Expression in Breast Cancer is Now Detectable by Indica Labs’ Breast IHC AI Read More »

Free Demo
Free Demo
Scroll to Top